Compare Illumina, Inc. (ILMN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vital Farms Inc — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Vital Farms Inc trades at $13.16 (market cap $590.45M). The key difference: Illumina, Inc. is far larger — about 47.3× Vital Farms Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | VITL | |
|---|---|---|
Market Cap | $27.94B | $590.45M |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $52.41 |
52-Week Low | $91.00 | $8.28 |
Enterprise Value | $29.33B | $593.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Vital Farms (VITL) trades at $13.76, up 1.55% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 15.44% ROE and trades at a modest P/E of 13.25. Recent earnings have been mixed, with a Q3 2025 beat but Q1 2026 miss, while analyst sentiment remains positive with 56% buy ratings. Net cash flow is negative due to significant investing activities, and a class action lawsuit filed in May 2026 adds legal overhang.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term performance hinges on reversing negative earnings surprises and managing legal risks. The consensus price target of $13.50 suggests limited upside from current levels, with execution on revenue growth and margin stabilization key to driving shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
